Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics

Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA^® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.^1-3

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/

The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.^{4-7, 9,10} It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients.

Designed in collaboration with over 70 aesthetics practitioners, the next-generation Restylane syringe was optimized for ergonomic functionality, ease of aspiration, ease of operation, and a premium look and feel, resulting in an innovative syringe that supports practitioners with delivering premium results. ^4,5,7,9 Additionally, the syringe was designed with sustainability in mind, with compact paper-only carton packaging that is 100% recyclable and reduces in-clinic waste by up to 30% based on volume reduction. ^8,11

Galderma’s versatile Restylane portfolio is the only hyaluronic acid (HA) range offering four distinct technologies, NASHA^®, NASHA HD™, OBT™, and SB-NASHA™, that offer firmer gels that provide contouring and structural support, to soft, flexible formulations that smooth facial lines and wrinkles for a more youthful look.^12-19 With HA closest to the skin’s own, it is designed to deliver personalized, natural-looking outcomes that provide contour, definition, and hydration, meeting diverse patient needs across key areas of the face, décolletage, and in the hands.^12-15,20-22 The new state-of-the-art syringe represents the next step in Restylane’s evolution, with a novel way to deliver its trusted premium results.

The next-generation syringe is now approved for use in the EU, the U.S., and Canada with the NASHA^® lidocaine range of Restylane products including, Restylane Lyft™ Lidocaine, Restylane Eyelight™ and Restylane-L™ (known as Classyc™ Lidocaine in some markets).^1-3

With over 30 years of innovation and more than 77 million treatments administered worldwide, Restylane’s has an iconic heritage as a trusted, science-backed HA treatment that consistently delivers premium results. ^23,24 Building on this heritage, the new state-of-the-art Restylane syringe demonstrates Galderma’s continued innovation, and solidifies its position at the forefront of aesthetics.

About the Restylane portfolio

Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results. ^21,25-27 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.^28-31 Powered by NASHA^®, NASHA HD™, OBT™ and SB-NASHA™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.^12-19 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.^12,21,22

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224651688/en/

© Business Wire, Inc.

Advertencia :
Este comunicado de prensa no es un documento producido por AFP. AFP no será responsable de su contenido. Para cualquier pregunta relacionada, por favor póngase en contacto con las personas/entidades mencionadas en el comunicado de prensa.